Adage Capital Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Adage Capital Partners’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,400,000	Closed	-$36.6M	–	742
2018 Q4	$36.6M	Sell	1,400,000 -100,000	-7%	-$2.35M	0.1%	224
2018 Q3	$34.4M	Buy	1,500,000 +100,000	+7%	+$2.04M	0.08%	293
2018 Q2	$26.7M	Hold	1,400,000	–	–	0.06%	339
2018 Q1	$23.6M	Buy	1,400,000 +1,205,459	+620%	+$20.2M	0.05%	359
2017 Q4	$2.96M	Buy	+194,541	New	+$2.89M	0.01%	651
2015 Q4	–	Sell	-750,000	Closed	-$8.46M	–	742
2015 Q3	$8.46M	Buy	750,000 +275,000	+58%	+$3.36M	0.02%	558
2015 Q2	$6.03M	Buy	475,000 +125,000	+36%	+$1.35M	0.02%	615
2015 Q1	$3.25M	Sell	350,000 -25,000	-7%	-$282K	0.01%	661
2014 Q4	$5.37M	Buy	+375,000	New	+$4.44M	0.01%	618

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners's VNDA Position: Q1 2019 in Review

Adage Capital Partners sold out of Vanda Pharmaceuticals (VNDA) in Q1 2019, closing a stake of 1,400,000 shares — an estimated $36.6M sold.

Adage Capital Partners first reported a position in VNDA in Q4 2014 and held it in 9 quarters. The position peaked at $36.6M in Q4 2018. 179 funds tracked by Wall St. Rank hold VNDA as of Q1 2019.

Adage Capital Partners reported no remaining Vanda Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Adage Capital Partners sold 1,400,000 Vanda Pharmaceuticals shares in Q1 2019, an estimated $36.6M.
Adage Capital Partners first reported a position in Vanda Pharmaceuticals in Q4 2014 and held it in 9 quarters.
Adage Capital Partners's Vanda Pharmaceuticals position peaked at $36.6M in Q4 2018.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2019.

Based on Adage Capital Partners's 13F filing for Q1 2019, filed 15 May 2019.